News Out on RS!!
http://www.prweb.com/releases/2012/7/prweb9736599.htm
EP Global Communications, Inc. Announces Friday July 27, 2012 as Effective Date for Approved Reverse Split Restructuring of the Company Begins as 100% of Major Debt is Removed from Balance Sheet
Irvine, CA (PRWEB) July 26, 2012
EP Global Communications, Inc. (the Company) , (Pink Sheets: EPGL.PK), announces that FINRA has set Friday July 27, 2012 as the market effective date for the 10:1 reverse split of common outstanding shares. The Company shareholders previously approved the reverse split on June 8, 2012. As a result, the Company will eliminate 100% of major debt and effectuate a new direction into the medical device manufacturing and marketing sector. The Company recently announced the appointment of Corey W. Hunter, MD as Medical Director and Chairman of the Scientific Advisory Board. Shareholders can expect additional announcements shortly. About EP Global Communications, Inc. EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body. Safe Harbor Statement Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
http://www.prweb.com/releases/2012/7/prweb9736599.htm
EP Global Communications, Inc. Announces Friday July 27, 2012 as Effective Date for Approved Reverse Split Restructuring of the Company Begins as 100% of Major Debt is Removed from Balance Sheet
Irvine, CA (PRWEB) July 26, 2012
EP Global Communications, Inc. (the Company) , (Pink Sheets: EPGL.PK), announces that FINRA has set Friday July 27, 2012 as the market effective date for the 10:1 reverse split of common outstanding shares. The Company shareholders previously approved the reverse split on June 8, 2012. As a result, the Company will eliminate 100% of major debt and effectuate a new direction into the medical device manufacturing and marketing sector. The Company recently announced the appointment of Corey W. Hunter, MD as Medical Director and Chairman of the Scientific Advisory Board. Shareholders can expect additional announcements shortly. About EP Global Communications, Inc. EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body. Safe Harbor Statement Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
